Argent Biopharma (ASX:RGT)
ASX announcement history & article coverage
Transparent by design.
Announcments by Argent Biopharma (ASX:RGT) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
RGT Executes Global Licence for Non-Core Cannabis Genetics
Argent BioPharma grants TPI exclusive global licence for four cannabis genotypes
Quarterly Activities/Appendix 4C Cash Flow Report
Argent BioPharma expands antiviral and veterinary licensing while reporting A$11,000 in quarter-end cash
Notice of Annual General Meeting/Proxy Form
Date of AGM and Closing Date for Director Nominations
Strategic Focus on Immune Modulation and Longevity
Application for quotation of securities - RGT
Execution of Loan Facility Agreement
Argent BioPharma secures US$500,000 in loan facilities for working capital and R&D
Proposed issue of securities - RGT
Argent Signs NLC Licence to Expand Antiviral Portfolio
Argent BioPharma licences NLC antiviral portfolio under US$15,000 monthly fee and tiered royalty structure
Notification of cessation of securities - RGT
Appendix 4E and 2026 Annual Report
Argent BioPharma reports $7.7M loss, secures global CannEpil licensing deal and $11M financing facility
Appendix 4G and Corporate Governance Statement
FDA-CVM Establish INAD File for CannEpil Veterinary Program
FDA Establishes INAD File for Argent BioPharma's CannEpil Veterinary Program
Proposed issue of securities - RGT
$250,000 in Funding Received under Financing Facility
US Veterinary Development Programme for CannEpil Commences
Argent BioPharma launches U.S. veterinary development program for CannEpil®
Notification of cessation of securities - RGT
CannEpil Global Licence Expands into Veterinary Healthcare
Argent BioPharma Expands CannEpil® License to Veterinary Market with New Royalty Stream
Quarterly Activities/Appendix 4C Cash Flow Report
Argent BioPharma secures global CannEpil license deal eliminating US$5.5m debt, advances veterinary asset acquisition and clinical progress
